Temsirolimus, sold under the brand name Torisel, is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in May 2007, and was also approved by the European Medicines Agency (EMA) in November 2007. It is a derivative and prodrug of sirolimus.
{{Drugbox | Verifiedfields = changed | verifiedrevid = 409344559 | IUPAC_name = (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate | image = Temsirolimus.svg | image_class = skin-invert-image
| tradename = Torisel | Drugs.com = | MedlinePlus = a607071 | licence_EU = yes | DailyMedID = Temsirolimus | licence_US = Torisel | pregnancy_AU = D | pregnancy_US = N | pregnancy_category = | legal_AU = S4 | legal_CA = Rx-only | legal_UK = POM | legal_US = Rx-only | legal_EU = Rx-only | legal_EU_comment = | legal_status = | routes_of_administration = Intravenous | ATC_prefix = L01 | ATC_suffix = EG01
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).